AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprising:

(a) a first plasmid DNA operably encoding a CEA; and

(b) a second plasmid DNA operably encoding a CD40 ligand;

together with a pharmaceutically acceptable carrier;

wherein both plasmid DNAs are operably incorporated in an attenuated bacterial delivery vector selected from the group consisting of *Salmonella typhimurium* and *Listeria monocytogenes*.

Claims 2-7 (cancelled).

Claim 8 (original). The DNA vaccine of claim 1 wherein both plasmid DNAs are operably incorporated in an attenuated *Salmonella typhimurium* delivery vector.

Claim 9 (original). The DNA vaccine of claim 1 wherein the CD40 ligand is CD40LT.

Claim 10 (currently amended). A method of immunizing a mammal against cancer cells that present a carcinoembryonic antigen (CEA) which comprises the step of administering to the mammal an effective immune response eliciting amount of a DNA vaccine comprising a first plasmid DNA operably encoding a CEA, and a second plasmid DNA operably encoding a CD40 ligand, in an amount sufficient to elicit an immune response against cells that present a CEA; wherein both plasmid DNAs are operably incorporated in an attenuated bacterial delivery vector selected from the group consisting of *Salmonella typhimurium* and *Listeria monocytogenes*..

Claim 11 (original). The method of claim 10 wherein the mammal is a human.

Claims 12-15 (cancelled).

Claim 16 (original). The method of claim 10 wherein the CD40 ligand is CD40LT.

Claim 17 (original). The method of claim 10 wherein the cells presenting a carcinoembryonic antigen are colon cancer cells.

Claim 18 (original). The method of claim 10 wherein the vaccine is administered orally.

Claims 19-35 (cancelled).

Claim 36 (new). A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprising:

(a) a first plasmid DNA operably encoding a CEA; and

(b) a second plasmid DNA operably encoding a CD40 ligand;

together with a pharmaceutically acceptable carrier;

wherein both plasmid DNAs are operably incorporated in an attenuated bacterial delivery vector.

Claim 37 (new). The DNA vaccine of claim 36 wherein the CD40 ligand is CD40LT.

Claim 38 (new). A method of immunizing a mammal against cancer cells that present a carcinoembryonic antigen (CEA) which comprises the step of administering to the mammal an effective immune response eliciting amount of a DNA vaccine of claim 36.

Claim 39 (new). The method of claim 38 wherein the mammal is a human.

Claim 40 (new). The method of claim 38 wherein the second plasmid DNA encodes CD40LT.

Claim 41 (new). The method of claim 38 wherein the cells presenting a carcinoembryonic antigen are colon cancer cells.

Claim 42 (new). The method of claim 38 wherein the vaccine is administered orally.